Gyre Therapeutics, Inc. (GYRE) Return on equity 2017–2025
Gyre Therapeutics, Inc. (GYRE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
15.8%FY2025 · since FY2017: -70.1% → 15.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 15.8% | -12.5 pp |
| FY2024 | 28.3% | — |
| FY2022 | 10.1% | +224.2 pp |
| FY2021 | -214.0% | -140.1 pp |
| FY2020 | -73.9% | — |
| FY2018 | -25.1% | +45.0 pp |
| FY2017 | -70.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Net marginGYRE Gross profitGYRE Gross marginGYRE Operating incomeGYRE Operating marginGYRE Operating cash flowGYRE Free cash flowGYRE Capital expendituresGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Total liabilitiesGYRE Shareholders’ equityGYRE overview →